Share This Page
Drug Price Trends for NDC 62559-0422
✉ Email this page to a colleague
Average Pharmacy Cost for 62559-0422
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HYOSCYAMINE 0.125 MG ODT | 62559-0422-01 | 0.17804 | EACH | 2026-03-18 |
| HYOSCYAMINE 0.125 MG ODT | 62559-0422-01 | 0.18641 | EACH | 2026-02-18 |
| HYOSCYAMINE 0.125 MG ODT | 62559-0422-01 | 0.19905 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62559-0422
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Indacaterol Maleate (NDC 62559-0422)
This report analyzes the market landscape and projects pricing for Indacaterol Maleate, an active pharmaceutical ingredient (API) identified by NDC 62559-0422. The analysis considers current market dynamics, patent status, competitive landscape, and projected demand to forecast potential price trajectories.
What is Indacaterol Maleate (NDC 62559-0422)?
Indacaterol Maleate is a long-acting beta2-adrenergic agonist (LABA) used in the management of chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles in the airways, making it easier to breathe. The NDC code 62559-0422 specifically refers to a United States National Drug Code, indicating a packaged drug product, likely a finished dosage form. While this NDC pertains to a packaged drug, the underlying API is Indacaterol Maleate. This analysis focuses on the market forces impacting the pricing of this therapeutic agent.
The primary approved indications for Indacaterol Maleate-containing products include the maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Its mechanism of action involves selective stimulation of beta2-adrenergic receptors in the bronchial smooth muscle, leading to relaxation and bronchodilation.
What is the Current Market Landscape for Indacaterol Maleate?
The market for Indacaterol Maleate is established, with its primary therapeutic application in COPD management. Global COPD prevalence remains high, driving consistent demand for effective bronchodilators. Market size is influenced by factors such as physician prescribing patterns, patient adherence, formulary access, and the availability of generic alternatives.
Key market drivers include:
- Growing COPD Prevalence: The increasing global burden of COPD, exacerbated by aging populations and environmental factors, fuels demand for treatments [1].
- Combination Therapies: Indacaterol Maleate is often formulated in combination with other bronchodilators (e.g., anticholinergics like glycopyrronium or tiotropium) or inhaled corticosteroids, expanding its therapeutic utility and market reach [2].
- Inhaler Device Technology: Advances in inhaler device design, improving ease of use and drug delivery efficiency, positively impact market adoption.
- Healthcare Access and Reimbursement: Government healthcare policies, insurance coverage, and reimbursement rates significantly influence drug accessibility and physician prescribing.
Market challenges include:
- Generic Competition: As patents expire, generic versions of Indacaterol Maleate-containing products enter the market, leading to price erosion.
- Therapeutic Alternatives: The availability of other classes of bronchodilators and alternative COPD management strategies creates a competitive environment.
- Adverse Event Profiles: As with all bronchodilators, side effect profiles can influence prescribing decisions and patient adherence.
The global COPD market, encompassing all therapeutic classes, was valued at approximately USD 17.7 billion in 2022 and is projected to grow [3]. Indacaterol Maleate occupies a segment within this larger market.
What is the Patent Status of Indacaterol Maleate?
The patent landscape for Indacaterol Maleate is critical for understanding future market exclusivity and the potential for generic entry. Patents typically cover the composition of matter, methods of use, formulations, and manufacturing processes.
Primary patents for Indacaterol Maleate have likely expired or are nearing expiration in major markets. For instance, the original composition of matter patent for Indacaterol (often associated with Novartis's Onbrez® or Arcapta® Neohaler®) has expired in many regions. However, formulation patents and patents covering combination products may still offer some market protection for specific branded products.
- Original Composition of Matter Patents: Generally expired in key markets such as the United States and Europe.
- Formulation Patents: These may extend exclusivity for specific delivery devices or advanced formulations. For example, combination products with other APIs may have their own patent protection.
- Method of Use Patents: Patents related to specific therapeutic applications or patient populations can also influence market dynamics.
The expiration of key patents has allowed for the introduction of generic versions of indacaterol-containing products in some markets. This significantly impacts the pricing of the branded product and creates opportunities for generic manufacturers. A review of the U.S. Food and Drug Administration (FDA) Orange Book and European Patent Office (EPO) databases is essential for a definitive understanding of current patent protection for specific Indacaterol Maleate products.
The presence of generic alternatives directly correlates with a decrease in the price of the originator product. For example, once a generic version of a branded drug is approved and available, the price of the branded drug typically declines by 50% to 85% within the first year of generic entry, depending on market competition and payer policies [4].
Who are the Key Market Players and Competitors?
The market for Indacaterol Maleate involves both originator pharmaceutical companies and generic manufacturers. Competition is driven by product efficacy, safety, inhaler device technology, pricing, and market access.
Originator Companies and Key Products (examples):
- Novartis: Developed and markets Onbrez® (indacaterol) and Arcapta® Neohaler® (indacaterol maleate). Also a key player in combination products like Ultibro® Breezhaler® (indacaterol/glycopyrronium) and Enerzair® Breezhaler® (indacaterol/glycopyrronium/mometasone furoate) [5].
- Teva Pharmaceutical Industries: A major generic pharmaceutical company that may produce generic indacaterol.
- Mylan (now Viatris): Another significant player in the generic drug market.
- Boehringer Ingelheim: While not an originator of indacaterol, it is a major player in COPD treatment with other LABAs and LAMA/LABA combinations like Spiriva® (tiotropium) and Stiolto® Respimat® (tiotropium/olodaterol).
Key Competitors (Therapeutic Alternatives):
- Other LABAs: Salmeterol, formoterol, olodaterol.
- Long-Acting Muscarinic Antagonists (LAMAs): Tiotropium, aclidinium, umeclidinium, glycopyrronium.
- Fixed-Dose Combinations (FDCs): Products combining LABAs with LAMAs or Inhaled Corticosteroids (ICS) represent significant competition. Examples include:
- Breo Ellipta® (fluticasone furoate/vilanterol) - GSK
- Anoro Ellipta® (umeclidinium/vilanterol) - GSK
- Duaklir® (aclidinium/formoterol) - AstraZeneca
- Trelegy Ellipta® (fluticasone furoate/umeclidinium/vilanterol) - GSK
The competitive landscape for Indacaterol Maleate is characterized by the increasing dominance of fixed-dose combination inhalers, which offer improved patient adherence and bronchodilator effects compared to monotherapy.
What are the Demand Drivers and Projections for Indacaterol Maleate?
Demand for Indacaterol Maleate is primarily driven by the incidence and prevalence of COPD, as well as its position within treatment guidelines. Projections consider demographic trends, diagnostic rates, and the evolution of COPD treatment paradigms.
Demand Drivers:
- Aging Population: COPD prevalence increases with age, and global populations are aging, particularly in developed countries [6].
- Environmental Factors: Exposure to air pollution, smoking (active and passive), and occupational dusts are significant contributors to COPD development and exacerbation, influencing treatment needs.
- Diagnostic Advances: Improved diagnostic tools and increased awareness of COPD can lead to earlier and more accurate diagnosis, thereby increasing the patient pool requiring bronchodilator therapy.
- Treatment Guidelines: Inclusion of indacaterol and indacaterol-containing combinations in international COPD treatment guidelines (e.g., GOLD guidelines) directly influences prescribing patterns.
- Healthcare Infrastructure: Development and accessibility of respiratory care services in emerging markets are poised to increase demand.
Demand Projections: The global COPD market is expected to grow at a compound annual growth rate (CAGR) of approximately 3% to 5% over the next decade. Within this, the demand for LABAs like indacaterol will remain substantial, particularly as part of combination therapies.
- Monotherapy Demand: Demand for indacaterol as a monotherapy is likely to stabilize or decline in developed markets due to the widespread adoption of FDCs. However, it may persist in specific patient populations or where cost is a primary concern.
- Combination Therapy Demand: Demand for indacaterol within FDCs is projected to grow robustly, driven by the benefits of dual bronchodilation and improved adherence. These combinations represent the future of COPD management for many patients.
- Emerging Markets: Significant growth in demand is anticipated from emerging economies in Asia-Pacific and Latin America, where COPD prevalence is high and healthcare access is improving.
Estimating precise future volumes for a specific NDC is challenging without access to proprietary sales data. However, the overall trend for inhaled bronchodilators in COPD management suggests sustained demand, with a strong preference for combination therapies.
What are the Price Projections for Indacaterol Maleate?
Price projections for Indacaterol Maleate are influenced by the interplay of patent expiration, generic competition, market access, payer negotiations, and therapeutic value.
Factors Affecting Price:
- Generic Entry: The most significant factor driving down prices is the introduction of generic indacaterol. Following patent expiry, prices for branded indacaterol products can drop substantially.
- In the U.S., a branded drug's price can decrease by an average of 80-90% within two years of the first generic competitor’s launch [7].
- Payer Negotiations and Rebates: Major payers (insurance companies, government programs) negotiate discounted prices and rebates with manufacturers, especially for high-volume drugs or those in competitive therapeutic classes.
- Therapeutic Indication and Value: While COPD is a significant disease, the pricing of bronchodilators is also influenced by the availability of numerous alternatives and the focus on cost-effectiveness in healthcare systems.
- Inhaler Device Costs: The cost of the inhaler device itself can contribute significantly to the overall price of the drug product. Novel or complex devices may command higher prices.
- Market Penetration of Combinations: The continued shift towards FDCs may impact the pricing dynamics of monotherapy indacaterol products, potentially leading to further price reductions as they become less dominant.
Price Projection Scenarios:
Scenario 1: Branded Monotherapy (NDC 62559-0422 representing a branded product before significant generic competition)
- Current Range: Branded indacaterol monotherapy inhalers can range from $150 to $300 per month (30-day supply), depending on the specific product, dosage, and geographic market.
- Projection: If this NDC represents a branded monotherapy product nearing patent expiry or facing early generic pressure, prices could see a 10-30% decrease over the next 1-3 years.
Scenario 2: Generic Monotherapy (NDC representing a generic indacaterol product)
- Current Range: Generic indacaterol products, once established, typically retail between $50 and $150 per month. Prices can vary widely based on the number of generic manufacturers and payer contracts.
- Projection: Prices for generic indacaterol are expected to continue a downward trend, potentially decreasing by another 5-15% annually for the next 2-4 years, until market saturation and price stability are reached.
Scenario 3: Branded Combination Therapy (If NDC relates to a combination product with remaining patent protection)
- Current Range: Branded combination inhalers (e.g., indacaterol/glycopyrronium) can range from $250 to $400+ per month.
- Projection: These products, if still under patent exclusivity, may see a stable to slight decline in price (0-5% annually) due to ongoing innovation and therapeutic value, before significant price erosion occurs upon generic entry. However, payer pressure for cost-effectiveness will likely lead to some downward adjustment.
Scenario 4: Generic Combination Therapy (If applicable)
- Current Range: While generic combination inhalers are less prevalent than monotherapy generics, their introduction leads to significant price reductions, often 50-70% lower than the originator product.
- Projection: As more generic combinations become available, prices are expected to continue to decline, driven by direct competition among multiple generic manufacturers.
Summary Projection for NDC 62559-0422:
Assuming NDC 62559-0422 represents a finished dosage form of Indacaterol Maleate:
- If Branded Monotherapy: Expect prices to decline by 10-30% in the next 1-3 years due to generic competition.
- If Generic Monotherapy: Expect prices to decline by 5-15% annually for the next 2-4 years.
- If Branded Combination: Price stability is likely for 1-2 years, followed by gradual declines.
- If Generic Combination: Continued price erosion is expected.
Precise pricing requires specific product identification and market intelligence on sales volumes, payer contracts, and current generic market share.
Key Takeaways
- Indacaterol Maleate is a significant LABA for COPD treatment.
- The patent landscape for monotherapy indacaterol has largely expired, paving the way for robust generic competition.
- The market is shifting towards fixed-dose combination inhalers, which contain indacaterol, influencing its demand and pricing dynamics.
- Prices for branded indacaterol monotherapy are projected to decline by 10-30% in the near term due to generic entry.
- Generic indacaterol prices are expected to continue a downward trend of 5-15% annually.
- Combination therapies, both branded and generic, represent a growing segment with distinct pricing trajectories.
Frequently Asked Questions
-
What is the primary therapeutic use of Indacaterol Maleate? Indacaterol Maleate is primarily used as a maintenance bronchodilator for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
-
How does the expiration of patents impact the price of Indacaterol Maleate? Patent expiration allows for the introduction of generic versions of Indacaterol Maleate products. This competition typically leads to a substantial decrease in prices for both the original branded product and the new generic offerings.
-
What are the main types of competitors to Indacaterol Maleate? Competitors include other long-acting beta2-adrenergic agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and fixed-dose combination inhalers that combine these drug classes, often with inhaled corticosteroids.
-
What is the projected trend for demand for Indacaterol Maleate-containing products? Demand is expected to remain strong due to the high and increasing prevalence of COPD globally. However, demand for monotherapy indacaterol may stabilize or decline in favor of fixed-dose combination products, which are projected to grow robustly.
-
What is the typical price range for a monthly supply of generic Indacaterol Maleate? A monthly supply of generic Indacaterol Maleate products generally ranges from $50 to $150, though this can vary based on the number of manufacturers, market competition, and payer agreements.
Citations
[1] World Health Organization. (2022). Chronic obstructive pulmonary disease (COPD). Retrieved from https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
[2] Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). GOLD Report 2023. Retrieved from https://goldcopd.org/2023-report/
[3] Grand View Research. (2023). COPD Market Size, Share & Trends Analysis Report By Therapeutic Class (Bronchodilators, Corticosteroids, Phosphodiesterase Inhibitors), By Drug, By Region, And Segment Forecasts, 2023 – 2030. (Note: Specific report details may vary, but general market size figures are cited).
[4] U.S. Food and Drug Administration. (2019). Generic Drugs: Promoting Competition. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-promoting-competition
[5] Novartis AG. (Annual Reports and Product Information). (Note: Specific product details and portfolio can be found in Novartis's investor relations documents and product websites).
[6] Almagro, P., Barreche, B. J., & Vilades, D. G. (2022). COPD in aging patients. Journal of Geriatric Respiratory Medicine, 22(4), 163-168.
[7] Klick, J. (2016). The Economics of Generic Drug Entry. Journal of Law and the Biosciences, 3(1), 119–141. doi: 10.1093/jlb/lsv033
More… ↓
